vaccin
uniqu
class
pharmaceut
product
meet
statutori
definit
drug
biolog
product
food
drug
cosmet
act
fd
c
act
defin
drug
part
intend
use
articl
intend
use
diagnosi
cure
mitig
treatment
prevent
diseas
prophylact
vaccin
differ
mani
drug
biolog
primarili
way
administ
larg
popul
particular
popul
young
healthi
peopl
prevent
rather
treat
diseas
mechan
action
risktobenefit
profil
although
subject
regul
biolog
product
vaccin
inher
difficult
develop
character
manufactur
pharmaceut
product
current
uslicens
vaccin
list
tabl
immun
major
compon
global
public
health
use
vaccin
result
prevent
million
death
case
morbid
annual
caus
infecti
diseas
around
world
vaccin
wide
use
global
imper
product
safe
effect
current
technolog
permit
assess
licensur
control
surveil
vaccin
major
challeng
nation
regulatori
author
nra
confront
steadili
increas
number
novel
product
complex
qualiti
concern
new
technic
issu
aris
rapid
scientif
advanc
furthermor
emerg
global
market
volum
vaccin
cross
intern
border
continu
increas
critic
regulatori
knowledg
experi
vaccin
share
approach
control
harmon
greatest
extent
possibl
need
strong
nation
regulatori
author
especi
regul
vaccin
recogn
worldwid
develop
countri
establish
government
regulatori
agenc
review
determin
safeti
effect
vaccin
howev
even
today
mani
develop
countri
establish
nra
although
nra
world
health
organ
use
consult
approach
involv
expert
committe
biolog
standard
biolog
unit
develop
regulatori
criteria
identifi
consolid
current
consensu
opinion
key
regulatori
issu
also
commun
nation
author
manufactur
guidanc
document
address
gener
issu
specif
product
mechan
nra
inform
scientif
background
need
assess
critic
issu
advis
regulatori
approach
methodolog
found
optim
ensur
global
suppli
uniformli
safe
effect
vaccin
highest
qualiti
center
biolog
evalu
research
cber
us
food
drug
administr
fda
nation
regulatori
author
unit
state
charg
ensur
safeti
puriti
effect
vaccin
unit
state
review
vaccin
applic
occur
among
cber
offic
vaccin
research
review
offic
complianc
biolog
qualiti
offic
biostatist
epidemiolog
develop
vaccin
intric
process
everi
step
life
cycl
test
materi
use
product
postlicensur
lotreleas
test
subject
stringent
oversight
cber
licensur
cber
continu
overse
product
perform
vaccin
ensur
continu
safeti
efficaci
fdacber
regulatori
review
staff
consist
intern
multidisciplinari
team
scientist
regulatori
public
health
profession
involv
continu
exchang
inform
outsid
scientif
commun
laboratori
research
collabor
particip
workshop
seminar
intern
confer
fda
also
reli
expertis
formal
advisori
committe
includ
expert
field
vaccinolog
microbiolog
infecti
diseas
immunolog
biostatist
epidemiolog
clinic
trial
design
extern
expert
committe
review
summari
document
prepar
fda
sponsor
make
recommend
product
develop
safeti
efficaci
addit
cber
work
close
counterpart
us
government
agenc
depart
health
human
servic
dhh
us
public
health
servic
ph
nation
vaccin
program
offic
nvpo
center
diseas
control
prevent
cdc
nation
institut
health
nih
health
resourc
servic
administr
hrsa
cdc
respons
among
thing
epidemiolog
regul
test
vaccin
norman
w
baylor
valeri
b
marshal
materi
chapter
public
domain
except
borrow
figur
tabl
typhoid
vaccin
live
oral
typhoid
vi
polysaccharid
vaccin
influenza
monoval
influenza
viru
vaccin
nation
stockpil
influenza
vaccin
live
quadrival
intranas
influenza
vaccin
live
intranas
japanes
enceph
vaccin
inactiv
japanes
enceph
vaccin
inactiv
adsorb
surveil
diseas
support
immun
program
advisori
committe
immun
practic
acip
make
recommend
vaccin
use
director
nvpo
coordin
vaccin
effort
throughout
ph
government
agenc
nih
respons
conduct
provid
fund
wide
varieti
biomed
research
hrsa
respons
among
mani
thing
manag
nation
vaccin
injuri
compens
program
import
collabor
us
govern
involv
vaccin
activ
includ
us
depart
defens
dod
depart
veteran
affair
consist
goal
harmon
enterpris
industri
directorategener
dg
enterpris
european
commiss
european
medicin
agenc
ema
fda
conclud
confidenti
arrang
septemb
cover
medicin
product
includ
vaccin
subject
evalu
author
central
procedur
europ
confidenti
arrang
allow
ema
european
commiss
fda
unit
state
exchang
inform
part
regulatori
process
type
inform
cover
arrang
includ
legal
regulatori
issu
scientif
advic
orphan
drug
design
inspect
report
market
author
procedur
postmarket
surveil
confidenti
arrang
review
meet
dg
enterpris
ema
fda
brussel
march
review
result
agreement
intensifi
exist
cooper
area
medicin
product
bring
focu
vaccin
includ
prepared
pandem
influenza
pediatr
medicin
medicin
rare
diseas
orphan
oncolog
pharmacogenom
fda
confidenti
agreement
nra
australia
austria
brazil
belgium
canada
council
europ
european
commiss
dg
sanco
denmark
drug
itali
drug
netherland
franc
germani
israel
japan
mexico
new
zealand
republ
ireland
singapor
south
africa
sweden
switzerland
unit
kingdom
although
nra
fda
relev
memorandum
understand
mou
without
confidenti
arrang
peopl
republ
china
russia
drug
vietnam
arrang
strengthen
interact
regulatori
author
contribut
improv
promot
protect
public
health
global
although
need
special
care
prepar
test
vaccin
antitoxin
foreseen
earli
develop
product
vaccin
biolog
predominantli
unregul
feder
govern
regul
biolog
vaccin
particular
unit
state
histor
respons
issu
safeti
us
congress
enact
biolog
control
act
contain
initi
concept
use
regul
biolog
major
tragedi
occur
st
loui
missouri
twenti
children
becam
ill
die
receiv
equinederiv
diphtheria
antitoxin
contamin
tetanu
toxin
discov
diphtheria
antitoxin
prepar
hors
serum
contamin
tetanu
bacilli
event
stimul
legisl
regul
sale
biolog
juli
biolog
control
act
sign
law
prohibit
transport
sale
biolog
unless
manufactur
possess
establish
product
licens
consider
legisl
follow
point
recogn
could
assur
puriti
control
limit
inspect
test
final
product
limit
test
techniqu
test
would
need
includ
materi
product
vari
differ
anim
use
product
therefor
effect
control
would
also
need
includ
control
manufactur
establish
product
question
gener
administ
directli
circulatori
system
digest
tract
remedi
measur
avail
drug
impur
control
potenc
particularli
import
note
proceed
led
develop
legisl
first
dose
prove
worthless
loss
time
produc
product
may
cost
patient
life
idea
form
import
start
ensur
vaccin
safeti
use
basi
ensur
safeti
effect
throughout
world
histori
vaccin
control
organ
develop
nation
one
increas
size
complex
chronolog
develop
us
biolog
control
author
summar
tabl
outlin
figur
us
congress
enact
anoth
signific
law
expand
public
health
marin
hospit
servic
led
creation
first
feder
agenc
public
health
issu
could
coordin
hygien
laboratori
princip
research
unit
servic
locat
washington
dc
within
organ
biolog
control
servic
assum
respons
regul
three
product
smallpox
vaccin
tetanu
antitoxin
diphtheria
antitoxin
product
defin
biolog
hygien
laboratori
reorgan
expand
renam
nation
institut
health
time
legisl
author
evolv
strengthen
regul
vaccin
biolog
congress
recodifi
biolog
control
act
part
us
public
health
servic
act
ph
act
ph
act
incorpor
biolog
control
act
section
ph
act
usc
act
ph
act
focus
primarili
extens
control
manufactur
method
ensur
puriti
safeti
maintain
licensur
system
manufactur
facil
product
uniqu
ph
act
congress
explicit
addit
requir
biolog
manufactur
demonstr
potenc
measur
clinic
use
amend
ad
vaccin
blood
blood
compon
deriv
allergen
product
statutori
list
origin
act
govern
inspector
author
inspect
manufactur
establish
determin
whether
product
correctli
label
name
product
name
address
licens
number
manufactur
expir
date
product
determin
manner
product
prepar
section
act
also
permit
ph
manufactur
biolog
product
need
aris
eg
product
could
obtain
alreadi
licens
establish
author
use
date
throughout
life
ph
act
congress
vest
administr
author
regul
biolog
sever
separ
agenc
biolog
control
laboratori
join
nih
divis
infecti
diseas
divis
tropic
diseas
form
nation
microbiolog
institut
later
renam
nation
institut
allergi
infecti
diseas
administr
author
regul
biolog
origin
grant
nation
microbiolog
institut
need
strengthen
expand
control
biolog
becam
evid
time
mani
biolog
blood
product
well
vaccin
licens
includ
inactiv
polioviru
vaccin
prepar
monkey
kidney
cell
cultur
unfortun
sever
batch
vaccin
use
immun
number
children
develop
poliomyel
formaldehyd
inactiv
safeti
test
procedur
employ
inadequ
determin
retrospect
batch
could
shown
contain
live
polioviru
later
review
indic
incomplet
inactiv
vaccin
caus
poliomyel
vaccin
recipi
famili
contact
commun
contact
result
muchpublic
cutter
incid
cutter
manufactur
vaccin
administr
author
regul
biolog
transfer
congress
divis
biolog
standard
db
newli
creat
divis
within
nih
prior
regul
biolog
nih
focus
primarili
ph
act
requir
safeti
puriti
potenc
subsequ
congress
adopt
consum
safeti
act
transfer
regulatori
author
administr
ph
act
nih
fda
db
charg
administ
enforc
modern
regul
biolog
synchron
review
process
drug
elimin
requir
establish
licens
biolog
expedit
approv
mechan
lifethreaten
condit
author
fdama
well
fda
amend
act
fdaaa
includ
titl
ad
mani
new
provis
fd
c
act
act
reauthor
amend
sever
drug
medic
devic
provis
provid
fda
addit
respons
new
author
pdufa
iv
reauthor
fdaaa
outlin
review
perform
goal
drug
biolog
licens
applic
supplement
resubmiss
meet
manag
goal
clinic
hold
major
disput
resolut
special
protocol
question
assess
agreement
electron
applic
submiss
disciplin
review
complet
respons
letter
provis
fdaaa
signific
impact
regul
vaccin
review
process
contain
titl
iv
pediatr
research
equiti
act
prea
titl
ix
enhanc
author
regard
postmarket
safeti
drug
titl
ix
provid
fda
new
fund
collect
develop
review
safeti
inform
develop
advers
event
surveil
system
analyt
tool
titl
iv
expand
pediatr
research
reauthor
best
pharmaceut
children
act
pediatr
research
equiti
act
collect
author
afford
cber
author
acceler
improv
review
process
fda
cber
regul
vaccin
biolog
cber
current
legal
author
regul
vaccin
deriv
primarili
section
ph
act
certain
section
fd
c
act
statut
ph
act
implement
regul
codifi
code
feder
regul
cfr
cfr
publish
annual
contain
chang
regul
occur
previou
year
publish
feder
regist
regul
adopt
conform
administr
procedur
act
thu
regul
establish
repeal
revis
must
propos
publish
feder
regist
invit
interest
individu
parti
comment
within
prescrib
time
commonli
period
sever
month
comment
receiv
evalu
consid
fda
public
final
regul
feder
regist
titl
cfr
part
contain
regul
specif
applic
vaccin
biolog
addit
vaccin
meet
legal
definit
drug
fd
c
act
manufactur
must
compli
regul
current
good
manufactur
practic
cgmp
part
regul
applic
vaccin
biolog
product
summar
tabl
regul
cover
method
establish
standard
pertain
manufactur
biolog
product
ensur
product
safe
meet
qualiti
puriti
characterist
claim
manufactur
also
requir
perform
clinic
trial
eg
cfr
singl
set
basic
regulatori
requir
appli
vaccin
regardless
technolog
use
produc
regulatori
approv
criteria
contain
titl
cfr
also
appli
vaccin
regardless
indic
intend
target
popul
section
ph
act
usc
state
biolog
licens
applic
approv
demonstr
biolog
product
subject
applic
safe
pure
potent
b
facil
biolog
product
manufactur
process
pack
held
meet
standard
design
assur
biolog
product
continu
safe
pure
potent
pertin
oper
definit
biolog
contain
statut
cfr
follow
section
ph
act
defin
biolog
product
viru
therapeut
serum
toxin
antitoxin
vaccin
blood
blood
compon
deriv
allergen
product
analog
product
applic
prevent
treatment
cure
diseas
condit
human
thu
vaccin
clearli
regul
biolog
product
safeti
defin
rel
freedom
harm
effect
peopl
affect
directli
indirectli
product
prudent
administ
take
consider
charact
product
relat
condit
recipi
time
thu
properti
safeti
rel
ensur
absolut
sens
puriti
defin
rel
freedom
extran
matter
regardless
whether
harm
recipi
deleteri
product
usual
concept
puriti
safeti
coincid
puriti
often
relat
freedom
materi
pyrogen
adventiti
agent
chemic
use
manufactur
product
potenc
defin
specif
abil
capac
product
indic
appropri
laboratori
test
adequ
control
clinic
data
obtain
administr
product
manner
intend
effect
given
result
potenc
thu
defin
equival
concept
product
must
abl
perform
claim
possibl
must
correspond
measur
effect
recipi
correl
quantit
laboratori
find
standard
mean
specif
procedur
applic
establish
manufactur
releas
product
design
ensur
continu
safeti
puriti
potenc
biolog
product
word
standard
also
use
secondari
mean
usual
sens
refer
prepar
bacteri
viral
antigen
use
evalu
potenc
case
safeti
puriti
regul
regard
biolog
product
addit
defin
effect
reason
expect
signific
proport
target
popul
pharmacolog
effect
biolog
product
administ
adequ
direct
use
warn
unsaf
use
serv
clinic
signific
function
diagnosi
cure
mitig
treatment
prevent
diseas
human
current
good
manufactur
practic
defin
qualiti
system
manufactur
use
build
qualiti
product
regul
outlin
minim
manufactur
qualitycontrol
qualityassur
requir
prepar
drug
biolog
product
commerci
distribut
exampl
approv
product
develop
produc
accord
cgmp
safe
properli
identifi
correct
strength
pure
high
qualiti
fda
also
period
publish
variou
guidelin
guidanc
document
regard
manufactur
clinic
evalu
biolog
document
publish
fda
forc
law
intend
provid
use
time
recommend
applic
vaccin
list
tabl
guidanc
document
particularli
use
mean
agenc
provid
recommend
regulatori
requir
biolog
product
cover
entir
life
cycl
product
preinvestig
new
drug
ind
stage
premarket
consist
variou
ind
phase
prelicensur
postmarket
stage
preind
stage
consist
laboratori
develop
preclin
test
candid
vaccin
develop
manufactur
process
clinic
develop
new
drug
unit
state
usual
begin
sponsor
approach
fda
permiss
conduct
clinic
studi
investig
product
submiss
ind
applic
form
requir
found
ind
regul
sponsor
encourag
request
preind
meet
fda
discuss
preclin
studi
clinic
studi
design
data
requir
requir
resolut
initi
clinic
trial
prior
initi
phase
clinic
trial
sponsor
discuss
reach
agreement
preclin
studi
prior
preind
meet
fda
consider
studi
evalu
productspecif
basi
requir
may
differ
depend
type
vaccin
manufactur
process
mechan
action
preclin
toxic
studi
adequ
identifi
character
potenti
toxic
effect
vaccin
order
conclud
reason
safe
proceed
clinic
investig
target
popul
vaccin
includ
pregnant
women
women
childbear
potenti
development
toxic
studi
may
consid
adequ
inform
provid
fda
clinic
plan
protocol
submit
cber
review
prior
initi
anim
studi
toxic
studi
report
submit
new
ind
master
file
addit
toxic
studi
may
necessari
productclin
develop
continu
applic
sponsor
describ
composit
sourc
method
manufactur
product
method
use
test
safeti
puriti
potenc
provid
summari
laboratori
preclin
anim
test
provid
descript
propos
clinic
studi
name
qualif
clinic
investig
fda
maximum
day
review
origin
ind
applic
determin
whether
studi
particip
expos
unaccept
risk
part
ind
process
clinic
investig
file
inform
describ
qualif
perform
clinic
trial
detail
propos
studi
assur
number
condit
specifi
regul
met
sign
inform
consent
must
obtain
studi
particip
approv
studi
must
obtain
advanc
local
institut
review
board
regul
also
cover
evalu
preclin
laboratori
anim
studi
undertaken
support
use
product
human
licens
vaccin
may
ship
one
state
anoth
howev
premarket
phase
interst
shipment
product
investig
use
allow
law
regul
gener
three
separ
phase
clinic
evalu
experiment
biolog
premarket
stage
figur
phase
may
overlap
clinic
test
may
highli
iter
multipl
phase
trial
may
perform
new
data
obtain
phase
trial
intend
primarili
provid
preliminari
evalu
safeti
immunogen
trial
typic
conduct
small
number
eg
close
monitor
adult
volunt
ultim
target
popul
vaccin
infant
young
children
commonli
case
product
usual
evalu
stepwis
progress
older
younger
age
group
first
year
life
alway
simpl
distinguish
phase
phase
studi
howev
gener
phase
studi
larger
perhap
involv
sever
hundr
particip
phase
studi
often
random
well
control
provid
inform
safeti
immunogen
dosagerang
studi
includ
phase
clinic
develop
case
phase
studi
provid
preliminari
data
vaccin
activ
infecti
diseas
interest
intermedi
clinic
studi
may
done
phase
consid
efficaci
studi
studi
refer
socal
phase
studi
regulatori
definit
phase
design
assist
determin
whether
move
candid
vaccin
larger
phase
trial
phase
studi
sponsor
may
individu
physician
univers
hospit
commerci
firm
well
govern
agenc
one
institut
nih
cdc
dod
gener
smaller
pivot
phase
trial
design
statist
power
requir
phase
studi
data
phase
studi
encourag
phase
efficaci
studi
still
requir
support
licensur
candid
vaccin
phase
studi
may
increas
clinic
develop
time
vaccin
howev
phase
studi
may
use
evalu
screen
differ
vaccin
candid
phase
studi
use
evalu
candid
hiv
vaccin
done
prior
larg
phase
efficaci
trial
human
papillomaviru
vaccin
phase
studi
largescal
trial
involv
extens
test
provid
thorough
assess
safeti
well
definit
assess
efficaci
moreov
studi
often
includ
pivot
efficaci
trial
well
expand
safeti
studi
gener
consider
clinic
studi
support
licensur
vaccin
includ
demonstr
safeti
efficaci
immunogen
may
suffici
case
evalu
simultan
administr
licens
vaccin
ideal
efficaci
demonstr
random
doubleblind
wellcontrol
trial
endpoint
product
specif
may
clinic
diseas
endpoint
immun
respons
endpoint
efficaci
clinic
diseas
previous
establish
immun
correl
surrog
protect
recent
year
interconnect
variabl
studi
design
incid
diseas
prevent
efficaci
trial
variou
vaccin
involv
broad
rang
number
studi
particip
thousand
ten
thousand
exampl
clinic
diseas
endpoint
studi
design
demonstr
new
vaccin
inferior
alreadi
exist
product
type
gener
requir
larger
number
new
vaccin
compar
control
activ
clinic
diseas
incid
diseas
prevent
studi
popul
also
import
exampl
convinc
evid
effect
plasmaderiv
hepat
b
vaccin
popul
high
risk
requir
vaccine
placebo
recipi
contrast
trial
show
pneumococc
polysaccharid
conjug
vaccin
success
prevent
low
incid
invas
diseas
caus
streptococcu
pneumonia
capsular
serotyp
includ
vaccin
enrol
close
children
random
equal
receiv
pneumococc
conjug
vaccin
unrel
control
vaccin
immunogen
studi
may
request
provid
data
immun
respons
target
popul
vaccin
differ
popul
efficaci
studi
done
studi
known
bridg
studi
word
immunogen
data
may
use
bridg
exist
clinic
endpoint
efficaci
data
fda
guidanc
industri
provid
clinic
evid
effect
recommend
two
efficaci
trial
standard
howev
one
trial
may
adequ
result
compel
often
case
vaccin
clinic
endpoint
efficaci
trial
eg
robustdata
multicent
trial
high
level
efficaci
safeti
one
import
consider
evalu
new
vaccin
modif
current
licens
vaccin
initi
respons
determin
vaccin
safeti
start
clinic
investig
vaccin
manufactur
fda
respons
ensur
clinic
trial
done
good
clinic
practic
requir
essenti
evalu
safeti
data
intend
support
licens
applic
gener
evalu
safeti
one
must
compar
risk
vaccineprevent
diseas
risk
advers
event
potenti
associ
vaccin
may
chang
time
exampl
report
associ
rotashield
rotaviru
vaccin
live
oral
tetraval
manufactur
wyeth
intussuscept
result
addit
requir
evalu
safeti
rotateq
live
oral
pentaval
humanbovin
reassort
rotaviru
vaccin
manufactur
merck
respect
intussuscept
clinic
trial
enrol
infant
divid
equal
rotateq
placebo
primari
safeti
hypothesi
oral
rotateq
would
increas
risk
intussuscept
rel
placebo
within
day
dose
intend
target
popul
also
taken
consider
assess
adequaci
safeti
databas
routin
administ
childhood
vaccin
unit
state
target
popul
would
birth
cohort
unit
state
approxim
millionyear
gener
healthi
popul
govern
bodi
eg
state
local
govern
may
mandat
vaccin
common
reaction
studi
adequ
hundr
individu
mani
thousand
requir
defin
lowincid
advers
reaction
vaccin
evalu
clinic
endpoint
efficaci
trial
larg
safeti
databas
like
deriv
doubleblind
random
wellcontrol
efficaci
studi
howev
vaccin
evalu
immunogen
endpoint
studi
addit
studi
like
need
obtain
adequ
safeti
databas
addit
control
safeti
studi
often
request
number
subject
includ
efficaci
studi
deem
insuffici
provid
adequ
safeti
data
studi
need
design
way
statist
method
appli
evalu
safeti
studi
may
unblind
number
inject
rout
administr
schedul
differ
group
particular
infant
young
children
involv
phase
safeti
studi
provid
data
common
local
system
reaction
studi
vaccin
phase
clinic
develop
also
includ
immunogen
preliminari
safeti
data
concurr
administr
studi
vaccin
vaccin
relev
phase
safeti
studi
design
evalu
less
common
reaction
may
unequ
random
may
simplifi
trial
design
assess
less
common
advers
event
larg
trial
vaccin
recommend
schedul
routin
recommend
vaccin
safeti
immunogen
data
obtain
prelicensur
studi
support
simultan
administr
ind
studi
near
complet
complet
sponsor
believ
adequ
data
demonstr
product
safe
effect
intend
use
sponsor
may
appli
licens
manufactur
distribut
product
precis
product
method
procedur
defin
stage
manufactur
process
standard
submiss
biolog
licens
applic
bla
prebla
meet
fda
strongli
encourag
discuss
sponsor
product
develop
plan
fda
determin
delay
associ
initi
review
bla
reduc
avoid
exchang
sponsor
agenc
concern
propos
market
applic
primari
purpos
exchang
uncov
major
unresolv
problem
identifi
studi
sponsor
reli
adequ
suffici
well
control
establish
product
effect
identifi
statu
ongo
studi
acquaint
fda
review
gener
inform
submit
bla
includ
technic
inform
review
method
use
statist
analysi
data
discuss
best
approach
present
format
data
applic
arrang
meet
initi
sponsor
divis
respons
review
ind
histor
two
licens
applic
requir
submiss
one
product
one
establish
product
manufactur
howev
result
enact
fdama
bla
requir
bla
contain
detail
inform
product
clinic
manufactur
well
inform
concern
manufactur
facil
equip
obtain
biolog
licens
new
vaccin
section
ph
act
applic
submit
bla
director
cber
offic
vaccin
research
review
ovrr
applic
contain
data
deriv
nonclin
laboratori
clinic
studi
demonstr
manufactur
product
meet
prescrib
requir
safeti
puriti
potenc
bla
contain
inform
support
complianc
standard
address
requir
organ
personnel
build
facil
equip
control
compon
contain
closur
product
process
control
packag
label
control
hold
distribut
laboratori
control
record
maintain
furthermor
full
descript
manufactur
method
data
establish
stabil
product
date
period
sampl
repres
product
introduct
deliveri
introduct
interst
commerc
summari
test
result
perform
lot
repres
submit
sampl
specimen
label
enclosur
contain
address
locat
involv
manufactur
biolog
product
includ
bla
fda
provid
sponsor
use
advic
prepar
bla
well
adequaci
inform
support
bla
sponsor
submit
follow
inform
ovrr
applic
divis
within
week
advanc
meet
depend
type
meet
execut
summari
clinic
studi
submit
applic
propos
format
organ
submiss
includ
method
present
data
inform
statu
need
ongo
studi
inform
discuss
meet
applic
biolog
licens
consid
file
accept
agenc
review
cber
determin
receiv
pertin
inform
data
applic
regard
cber
refus
file
bla
deem
submiss
incomplet
addit
manufactur
facil
must
inspectionreadi
time
bla
submit
applic
also
requir
includ
either
environment
assess
claim
categor
exclus
requir
submit
environment
assess
environment
impact
statement
intern
cber
multidisciplinari
committe
perform
scientif
review
bla
member
review
committe
select
basi
expertis
requir
review
applic
process
occur
bla
supplement
bla
signific
chang
propos
review
discuss
exchang
correspond
sponsor
cber
review
committe
concern
issu
may
aris
fda
review
bla
announc
prior
approv
inspect
pai
manufactur
facil
perform
inspect
design
indepth
review
facil
record
total
product
process
method
equip
qualiti
control
procedur
personnel
implement
bla
process
chang
occur
scope
issu
review
pai
instead
manufactur
submit
detail
record
bla
regard
studi
clean
valid
monitor
data
pharmaceuticalgrad
water
facil
support
system
eg
clean
steam
compress
air
build
manag
system
facilityrel
system
detail
review
type
data
done
site
pai
pai
tend
requir
longer
period
time
fda
inspector
facil
increas
scope
issu
review
site
licensur
deni
inspect
origin
licens
applic
reinspect
occur
assur
receiv
defici
basi
denial
correct
cber
review
entir
packag
inform
bla
advisori
committe
vaccin
relat
biolog
product
advisori
committe
vrbpac
consult
need
ask
review
comment
adequaci
data
support
safeti
efficaci
target
popul
standard
safeti
efficaci
rel
benefittorisk
ratio
biolog
product
consid
regul
standard
allow
rang
safeti
efficaci
scientif
appropri
vrbpac
advic
serious
consid
cber
decis
regard
licensur
develop
recommend
use
given
packag
insert
committe
may
recommend
addit
studi
perform
either
approv
compon
bla
review
includ
product
label
describ
indic
use
contraind
dosag
possibl
advers
effect
protocol
manufactur
test
number
product
lot
specifi
establish
consist
process
confirmatori
test
result
within
cber
sampl
inprocess
materi
product
final
contain
conform
exist
regul
cber
determin
data
inform
applic
satisfactori
support
safeti
efficaci
product
product
licens
mechan
advanc
new
vaccin
review
process
develop
sever
lifethreaten
ill
mechan
includ
fasttrack
develop
well
acceler
approv
prioriti
review
market
applic
fast
track
program
fda
design
facilit
develop
expedit
review
new
drug
biolog
intend
treat
seriou
lifethreaten
condit
demonstr
potenti
address
unmet
medic
need
acceler
approv
cfr
may
grant
certain
biolog
product
studi
safeti
effect
treat
seriou
lifethreaten
ill
provid
meaning
therapeut
benefit
exist
treatment
approv
base
adequ
wellcontrol
clinic
trial
establish
product
effect
surrog
endpoint
reason
like
base
epidemiolog
therapeut
pathophysiolog
evid
predict
clinic
benefit
approv
pathway
subject
requir
sponsor
studi
biolog
product
verifi
describ
clinic
benefit
uncertainti
relationship
surrog
endpoint
clinic
benefit
recent
option
pursu
acceler
approv
pathway
trival
inactiv
influenza
vaccin
becam
avail
sponsor
shortag
influenza
vaccin
exist
us
market
time
new
vaccin
approv
case
fda
interpret
acceler
approv
regul
allow
acceler
approv
influenza
vaccin
shortag
influenza
seriou
sometim
lifethreaten
ill
fda
use
regulatori
mechan
approv
four
trival
inactiv
influenza
vaccin
glaxosmithklin
gsk
fluarix
id
biomed
corpor
flulav
novarti
agriflu
csl
afluria
acceler
approv
recent
use
licens
new
haemophilu
influenza
vaccin
hiberix
manufactur
gsk
acceler
approv
regul
give
fda
flexibl
respect
type
endpoint
reli
support
market
approv
affect
quantiti
qualiti
evid
need
demonstr
substanti
evid
effect
safeti
endpoint
consid
appropri
reli
support
approv
whether
surrog
endpoint
clinic
endpoint
must
support
substanti
evid
effect
product
regul
cber
elig
prioriti
review
provid
signific
improv
safeti
effect
treatment
diagnosi
prevent
seriou
lifethreaten
diseas
fda
month
complet
review
new
bla
design
prioriti
oppos
month
complet
review
standard
bla
submiss
fda
amend
biolog
product
regul
incorpor
cfr
approv
biolog
product
human
efficaci
studi
ethic
feasibl
rule
refer
anim
rule
allow
use
anim
efficaci
data
lieu
human
efficaci
data
human
challeng
studi
conduct
ethic
field
efficaci
studi
feasibl
infecti
diseas
epidemiolog
case
vaccin
situat
certain
drug
biolog
product
eg
vaccin
intend
reduc
prevent
seriou
lifethreaten
condit
caus
lethal
perman
disabl
toxic
chemic
biolog
radiolog
nuclear
substanc
may
approv
market
base
evid
effect
deriv
appropri
studi
anim
addit
support
data
safeti
pharmacokinet
immunogen
data
still
necessari
human
anim
rule
fda
licensur
product
safeti
establish
requir
cfr
met
base
adequ
wellcontrol
anim
trial
result
anim
studi
establish
product
reason
like
provid
clinic
benefit
human
fda
reli
evid
anim
studi
provid
substanti
evid
efficaci
product
follow
criteria
met
reason
well
understood
pathophysiolog
mechan
toxic
chemic
biolog
radiolog
nuclear
substanc
amelior
prevent
product
effect
demonstr
one
anim
speci
expect
react
respons
predict
human
unless
effect
demonstr
singl
anim
speci
repres
suffici
well
character
anim
model
word
model
adequ
evalu
respons
predict
respons
human
anim
endpoint
clearli
relat
desir
benefit
human
gener
enhanc
surviv
prevent
major
morbid
data
inform
pharmacokinet
pharmacodynam
product
relev
data
inform
anim
human
suffici
well
understood
allow
select
effect
dose
human
reason
expect
efficaci
product
anim
reliabl
indic
efficaci
human
anim
rule
appli
product
approv
basi
standard
describ
elsewher
fda
regul
eg
acceler
approv
base
surrog
marker
clinic
endpoint
surviv
irrevers
morbid
approv
product
anim
rule
requir
earli
multipl
discuss
fda
applic
need
detail
justif
efficaci
trial
feasibl
ethic
product
interest
begin
pivot
trial
pilot
studi
anim
expect
prospect
primari
endpoint
select
addit
regard
pivot
trial
prospect
statist
plan
place
fda
advisori
committe
also
may
consult
accept
anim
efficaci
trial
propos
agenc
review
bla
emerg
use
author
eua
anoth
regulatori
mechan
fda
acceler
avail
vaccin
pharmaceut
product
eua
fda
author
use
unapprov
product
unapprov
use
approv
product
emerg
potenti
emerg
exist
section
b
fd
c
act
amend
project
bioshield
act
allow
secretari
health
human
servic
author
introduct
interst
commerc
drug
devic
biolog
product
intend
use
actual
potenti
emerg
eua
issu
fda
secretari
must
declar
emerg
justifi
author
base
one
follow
determin
secretari
homeland
secur
domest
emerg
signific
potenti
emerg
involv
heighten
risk
attack
specifi
biolog
chemic
radiolog
nuclear
agent
agent
determin
secretari
defens
militari
emerg
signific
potenti
emerg
involv
heighten
risk
attack
specifi
biolog
chemic
radiolog
nuclear
agent
agent
determin
secretari
health
human
servic
public
health
emerg
section
ph
act
affect
signific
potenti
affect
nation
secur
involv
specifi
biolog
chemic
radiolog
nuclear
agent
agent
specifi
diseas
condit
may
attribut
agent
agent
new
rout
administr
contain
pediatr
assess
unless
applic
obtain
waiver
deferr
fda
prea
pediatr
assess
must
contain
data
adequ
assess
safeti
effect
drug
biolog
product
claim
indic
relev
pediatr
subpopul
data
support
dose
administr
pediatr
subpopul
product
safe
effect
fdaaa
reauthor
made
sever
chang
prea
primarili
enhanc
fda
oversight
applic
account
agreedon
pediatr
assess
new
provis
written
fdaaa
direct
fda
establish
intern
review
committe
pediatr
expertis
pediatr
review
committe
perc
committe
requir
provid
consult
fda
review
divis
pediatr
plan
assess
deferr
waiver
request
fdaaa
also
specifi
certain
label
chang
must
made
pursuant
applic
pediatr
assess
fdaaa
also
specifi
advers
event
report
requir
product
label
chang
result
pediatr
assess
specif
month
date
label
chang
made
advers
event
report
review
fda
pediatr
advisori
committe
pac
review
pac
make
recommend
regard
whether
fda
take
action
respons
report
whether
current
pharmacovigil
plan
adequ
modif
manufactur
process
may
occur
licensur
scaleup
chang
equip
optim
product
process
furthermor
clinic
studi
product
may
also
perform
licensur
manufactur
seek
addit
indic
product
use
eg
new
target
popul
would
benefit
vaccin
new
approv
manufactur
may
ask
commit
complet
specif
postmarket
socal
phase
studiesfor
exampl
provid
addit
assess
less
common
rare
advers
event
assess
durat
vaccineinduc
immun
studi
also
may
design
collect
addit
safeti
data
larg
number
vaccin
recipi
well
focu
issu
identifi
prelicensur
test
submiss
statu
report
certain
postmarket
studi
requir
regul
particular
requir
statu
report
pertain
postmarket
studi
clinic
safeti
efficaci
pharmacokinet
nonclin
toxicolog
applic
commit
write
licensur
manufactur
wish
significantli
modifi
manufactur
process
direct
vaccin
use
prior
approv
must
obtain
fda
chang
implement
applic
requir
submit
account
chang
appropri
licens
applic
past
sever
year
effort
made
simplifi
categor
manufactur
report
requir
facilit
implement
import
improv
product
process
test
method
equip
facil
make
chang
personnel
propos
chang
manufactur
method
substanti
potenti
advers
effect
safeti
effect
product
may
becom
effect
notif
given
cber
approv
chang
cfr
implement
classifi
chang
suffici
signific
regard
safeti
puriti
potenc
effect
product
requir
preapprov
supplement
applic
product
distribut
lesser
import
manufactur
must
provid
notif
day
distribut
product
made
use
chang
chang
manufactur
need
notifi
agenc
submiss
annual
report
guidanc
document
chang
approv
applic
biolog
product
avail
cber
web
site
wwwfdagovdownload
biologicsbloodvaccinesguidancecomplianceregulatoryinform
provid
detail
chang
regul
issuanc
licens
continu
surveil
product
manufactur
product
activ
licens
vaccin
sampl
submit
along
protocol
lot
prepar
firm
provid
detail
product
summari
test
result
although
requir
law
regul
cber
often
perform
select
laboratori
test
type
extent
confirmatori
test
perform
cber
depend
sever
factor
new
product
difficulti
may
arisen
manufactur
use
product
releas
reject
base
review
test
result
includ
done
manufactur
perform
cber
altern
offici
lot
releas
allow
provis
outlin
extens
character
product
track
record
continu
safeti
puriti
potenc
new
regul
develop
clearli
specifi
factor
evalu
includ
measur
allow
addit
product
consid
categori
consid
manufactur
must
abl
produc
vaccin
repeatedli
meet
standard
potenc
puriti
stabil
bulk
final
contain
materi
use
consist
process
import
factor
consid
natur
product
respect
correl
measur
potenc
biolog
activ
effect
surveil
sampl
protocol
may
requir
submit
cber
predetermin
interv
licens
establish
inspect
least
everi
year
except
facil
manufactur
influenza
vaccin
inspect
annual
purpos
inspect
determin
whether
licens
product
manufactur
test
describ
licens
applic
accord
applic
regul
manufactur
fail
meet
product
standard
complianc
cgmp
may
licens
suspend
revok
depend
natur
potenti
health
hazard
creat
major
issu
observ
inspect
categor
three
major
area
processrel
issu
qualiti
unitrel
issu
facilityand
product
environmentrel
issu
exampl
process
valid
issu
includ
lack
document
time
limit
major
step
product
process
lack
valid
rework
reprocess
step
manufactur
process
lack
data
support
inprocess
specif
qualiti
unitrel
issu
includ
appropri
report
outofspecif
result
process
deviat
includ
adequ
investig
caus
appropri
document
product
releas
adequ
train
personnel
facil
product
monitor
concern
includ
control
product
environ
appropri
monitor
heat
ventil
air
condit
system
perform
microbi
qualiti
eg
pressur
differenti
appropri
sampl
site
frequenc
sampl
concern
facil
includ
adequ
clean
sanit
storag
changeov
procedur
multiproduct
area
equip
inspect
team
find
cgmp
defici
alreadi
licens
facil
team
may
remain
facil
achiev
audit
provid
confid
abil
firm
reproduc
manufactur
safe
potent
product
section
titl
ix
fdaaa
revis
fd
c
act
ad
section
author
fda
requir
certain
postmarket
studi
clinic
trial
prescript
drug
biolog
product
approv
section
fd
c
act
section
ph
act
usc
section
fdaaa
also
creat
new
section
fd
c
act
author
fda
certain
circumst
requir
risk
evalu
mitig
strategi
safetyrel
label
chang
respect
fdaaa
fda
use
term
postmarket
commit
pmc
refer
studi
manufactur
commit
condit
approv
product
vaccin
studi
usual
intend
evalu
safeti
immunogen
product
pmc
agre
fda
applic
licensur
fdaaa
fda
requir
postmarket
studi
follow
situat
acceler
approv
product
approv
b
fd
c
act
section
ph
act
requir
postmarket
studi
demonstr
clinic
benefit
defer
pediatr
studi
studi
requir
prea
anim
efficaci
rule
approv
studi
demonstr
safeti
efficaci
human
requir
time
use
new
section
fd
c
act
fda
author
also
requir
postmarket
studi
clinic
trial
time
approv
approv
fda
becom
awar
new
safeti
inform
section
b
state
postmarket
studi
clinic
trial
may
requir
assess
known
seriou
risk
relat
use
drug
involv
assess
signal
seriou
risk
relat
use
drug
identifi
unexpect
seriou
risk
avail
data
indic
potenti
seriou
risk
advers
event
report
system
adequ
fda
defin
clinic
trial
prospect
investig
sponsor
investig
determin
method
assign
treatment
intervent
one
human
subject
studi
investig
investig
use
human
clinic
trial
defin
eg
observ
epidemiolog
studi
anim
studi
laboratori
experi
fda
issu
guidanc
industri
describ
type
studi
clinic
trial
requir
postmarket
requir
pmr
fdaaa
remain
agreedon
commit
pmc
pmr
describ
requir
postmarket
studi
clinic
trial
includ
requir
acceler
approv
prea
anim
rule
fdaaa
exampl
requir
studi
pharmacoepidemiolog
studi
design
assess
seriou
risk
trial
primari
safeti
endpoint
preclin
studi
investig
specif
endorgan
toxic
pharmacokinet
studi
indic
popul
potenti
risk
high
drug
exposur
could
result
toxic
studi
gener
would
consid
requir
postmarket
studi
clinic
trial
agreedon
studi
pmc
includ
biolog
qualiti
studi
manufactur
stabil
immunogen
studi
primari
safeti
endpoint
trial
primari
endpoint
relat
defin
efficaci
pharmacoepidemiolog
studi
design
examin
natur
histori
diseas
background
rate
advers
event
sinc
passag
fdaaa
sever
new
vaccin
approv
either
pmr
pmc
fda
author
monitor
progress
postmarket
studi
trial
requir
applic
submit
annual
statu
report
applic
requir
provid
timet
studi
complet
period
statu
report
statu
studi
includ
whether
enrol
begun
number
particip
enrol
expect
complet
date
whether
difficulti
complet
studi
encount
regulatori
review
cber
incorpor
manag
integr
regulatori
process
continu
discoveri
postmarket
call
manag
review
process
reli
strong
project
manag
infrastructur
regulatori
project
manag
rpm
essenti
member
review
team
rpm
coordin
review
regulatori
submiss
accord
cber
polici
procedur
regul
serv
among
function
facilit
drive
review
process
forward
project
manag
use
facilit
coordin
review
submiss
resolut
issu
biolog
product
develop
consist
four
phase
presubmiss
investig
market
postmarket
cber
manag
review
process
system
design
effect
effici
review
regulatori
submiss
target
phase
develop
manag
review
process
begin
sponsor
request
preind
meet
may
result
submiss
ind
eventu
bla
intern
review
process
cber
begin
initi
review
submiss
scientif
content
complianc
regul
member
multidisciplinari
review
team
select
basi
expertis
type
product
method
manufactur
respons
cber
review
compon
evalu
submiss
recommend
appropri
regulatori
action
facilit
approv
safe
effect
biolog
product
review
includ
evalu
chemistri
manufactur
control
inform
manufactur
facil
equip
preclin
clinic
data
safeti
efficaci
pharmacolog
toxicolog
suitabl
clinic
trial
design
analysi
clinic
data
deriv
trial
addit
review
monitor
conform
fda
regul
phase
biolog
product
develop
includ
postmarket
cber
scientist
also
perform
research
area
statist
epidemiolog
analysi
clinic
trial
design
chemistri
manufactur
control
specif
product
issu
contribut
polici
develop
surveil
activ
perform
ensur
safeti
biolog
product
compromis
activ
ensur
rapid
avail
approv
safe
effect
biolog
product
sponsor
encourag
avail
meet
cber
review
discuss
review
gener
clinic
development
plan
product
meet
sponsor
agenc
frequent
use
resolv
question
concern
rais
cours
clinic
investig
fda
encourag
meet
extent
aid
evalu
vaccin
resolv
scientif
issu
concern
product
gener
principl
underli
conduct
meet
free
full
open
commun
scientif
medic
question
may
aris
agreement
reach
pdufa
meet
eg
preind
ind
prebla
bla
meet
record
offici
minut
taken
fda
personnel
provid
sponsor
minut
along
written
materi
provid
sponsor
serv
perman
record
agreement
reach
bar
signific
scientif
develop
requir
otherwis
studi
conduct
accord
agreement
shall
presum
suffici
object
design
purpos
obtain
market
approv
drug
detail
inform
conduct
regulatori
meet
describ
cfr
preind
meet
particularli
import
new
sponsor
especi
product
incorpor
novel
featur
meet
also
encourag
critic
point
throughout
ind
review
includ
meet
purpos
meet
assess
adequaci
phase
safeti
immunogen
data
support
advanc
phase
evalu
phase
plan
draft
protocol
identifi
addit
inform
necessari
support
market
applic
use
investig
although
meet
design
primarili
ind
involv
new
molecular
entiti
new
vaccin
includ
combin
two
exist
vaccin
major
new
expand
indic
current
market
vaccin
sponsor
ind
may
request
obtain
meet
meet
held
major
commit
effort
resourc
specif
phase
studi
made
vaccin
test
prelicensur
well
postlicensur
phase
test
procedur
develop
combin
understand
past
advers
experi
best
current
knowledg
regard
potenti
new
one
past
experi
highli
import
issu
must
continu
receiv
special
attent
inactiv
vaccin
clear
understand
kinet
inactiv
key
lesson
cutter
incid
mention
previous
live
vaccin
agent
must
stabl
level
attenu
must
becom
overattenu
revert
virul
brazilian
experi
yellow
fever
vaccin
appear
revert
neurovirul
multipl
passag
demonstr
need
seed
lot
system
number
passag
parent
viru
passag
level
use
vaccin
restrict
vaccin
requir
extens
search
extran
contamin
experi
human
serum
use
stabil
yellow
fever
vaccin
caus
hundr
case
longincub
hepat
viru
infect
underscor
need
fda
requir
cell
substrat
vaccin
viral
seed
use
product
appropri
select
test
ensur
introduc
unintend
risk
current
cell
substrat
use
manufactur
licens
vaccin
primari
avian
monkey
cell
diploid
cell
one
continu
cell
line
vero
well
yeast
insect
cell
refer
tabl
list
cell
substrat
current
us
licens
vaccin
fda
publish
final
guidanc
character
qualif
cell
substrat
biolog
start
materi
use
product
viral
vaccin
prevent
treatment
infecti
diseas
guidanc
document
provid
import
advic
manufactur
use
cell
cultur
produc
vaccin
infecti
diseas
use
modern
technolog
ensur
meet
highest
safeti
expect
select
cell
substrat
influenc
safeti
puriti
biolog
product
manufactur
cell
substrat
evalu
casebycas
basi
character
cell
substrat
use
develop
manufactur
vaccin
address
certain
gener
issu
might
affect
safeti
puriti
vaccin
product
manufactur
exampl
issu
includ
karyotyp
tumorigen
phenotyp
cell
substrat
ident
genet
stabil
cell
substrat
viru
seed
requir
vaccin
free
extran
infecti
microorgan
potenti
oncogen
agent
histor
primari
cell
use
wide
viral
vaccin
product
although
primari
cell
still
use
manufactur
viral
vaccin
major
concern
arisen
passag
adventiti
agent
primari
cell
product
thu
potenti
vaccin
recipi
earli
exogen
endogen
contamin
primari
monkey
kidney
cell
pmkc
simian
viru
chicken
embryo
fibroblast
cef
avian
leukosi
viru
report
pmkc
cef
still
use
product
viral
vaccin
cell
requir
well
character
extens
test
prior
use
issu
relat
cell
substrat
discuss
varieti
forum
oncogen
defin
process
agent
immort
cell
endow
capac
form
tumor
demonstr
virus
oncogen
mammalian
host
produc
intens
focu
cellcultur
substrat
safeti
well
vaccin
manufactur
cell
substrat
deriv
tumor
develop
tumorigen
phenotyp
unknown
mechan
could
carri
higher
theoret
risk
contain
oncogen
substanc
import
character
cell
substrat
ensur
contain
potenti
oncogen
compon
could
contamin
final
product
epidem
bovin
spongiform
encephalopathi
bse
also
refer
mad
cow
diseas
possibl
relationship
human
variant
creutzfeldtjakob
diseas
vcjd
new
variant
cjd
special
concern
account
attent
center
safeti
substanc
deriv
mammalian
sourc
media
compon
use
nurtur
cell
cultur
gelatin
use
stabil
bovinederiv
materi
tradit
use
manufactur
mani
biolog
product
includ
vaccin
sinc
bse
first
recogn
unit
kingdom
fda
concern
elimin
potenti
contamin
biolog
product
bse
agent
concern
heighten
appear
vcjd
unit
kingdom
minim
possibl
contamin
product
fda
request
manufactur
use
materi
deriv
cattl
born
rais
slaughter
countri
bse
known
exist
fda
refer
manufactur
list
countri
maintain
us
depart
agricultur
wwwaphisusdagovimportexportanimalsanimalimportanimalimportsbseshtml
inform
vaccin
sourc
bovinederiv
raw
materi
found
cber
web
site
wwwfdagovbiologicsbloodvaccin
incept
recombin
dna
era
possibl
risk
induct
transform
cell
recipi
major
concern
issu
approach
care
studi
construct
use
stabil
construct
attempt
reduc
extran
dna
content
level
regard
extrem
unlik
produc
advers
genet
event
residu
dna
continu
nontumorigen
cell
lowpassag
vero
cell
limit
less
ngdose
parenter
inocul
less
oral
vaccin
cell
tumorigen
phenotyp
characterist
give
rise
special
concern
may
requir
stringent
limit
residu
dna
quantiti
ensur
product
safeti
preapprov
test
develop
may
conduct
entir
sponsor
involv
regulatori
agenc
well
cber
particularli
like
becom
involv
product
new
repres
novel
problem
test
involv
bolster
laboratorybas
capabl
one
strength
vaccin
regulatori
program
unit
state
product
move
forward
regulatori
process
sponsor
develop
test
program
greater
detail
final
test
method
must
establish
major
clinic
trial
efficaci
begin
manufactur
batch
product
use
demonstr
consist
manufactur
among
first
effort
product
develop
explor
potenc
assay
potenc
test
appli
product
demonstr
product
confer
protect
immun
type
test
vari
depend
product
commonli
base
studi
immunogen
protect
virul
challeng
laboratori
anim
howev
vitro
test
involv
includ
viru
titrat
eg
live
vaccin
polio
measl
mump
rubella
antigen
content
eg
influenza
inactiv
polioviru
vaccin
biochem
biophys
measur
eg
meningococc
conjug
vaccin
special
immunolog
assay
requir
clinic
develop
vaccin
ascertain
immunogen
vaccin
ideal
immun
respons
measur
assay
correl
protect
diseas
true
mani
current
licens
vaccin
howev
licens
vaccin
new
vaccin
develop
alway
clear
immun
respons
correl
protect
standard
immunogen
assay
across
studi
laboratori
across
similar
product
present
challeng
necessari
evalu
effect
vaccin
correl
sought
assay
result
preclin
later
clinic
test
result
prelicens
phase
research
test
result
evalu
determin
test
develop
need
appli
everi
batch
product
requir
repetit
exampl
hepat
b
vaccin
made
use
recombin
dna
technolog
initi
evid
ident
puriti
genet
stabil
protein
product
provid
physicochem
immunolog
molecular
biolog
test
method
consist
level
result
test
valid
multipl
lot
produc
ind
applic
productlicens
phase
determin
made
routin
perform
test
evalu
ensur
consist
qualiti
final
product
lot
regul
biolog
includ
requir
test
licens
product
certain
requir
gener
applic
product
wherea
other
tailor
specif
vaccin
test
gener
applic
product
includ
bacteri
fungal
steril
gener
safeti
puriti
ident
suitabl
constitu
materi
potenc
steril
test
perform
bulk
final
contain
materi
use
media
condit
incub
describ
regul
addit
cell
culturederiv
vaccin
must
test
mycoplasma
gener
safeti
test
usual
perform
intraperiton
inocul
final
contain
materi
mice
guinea
pig
detect
possibl
presenc
gross
extran
contamin
may
introduc
manufactur
fill
process
test
puriti
design
determin
product
free
extran
materi
except
unavoid
manufactur
process
describ
approv
licens
applic
may
includ
test
residu
moistur
pyrogen
substanc
final
contain
materi
must
identifi
test
specif
product
eg
neutral
compon
live
measl
mump
rubella
vaccin
specif
antisera
regard
constitu
materi
manufactur
must
ensur
ingredi
use
product
diluent
preserv
adjuv
meet
gener
accept
standard
puriti
adjuv
may
use
unless
adequ
proof
advers
affect
safeti
potenc
product
adjuv
use
current
licens
vaccin
unit
state
aluminum
salt
use
gsk
human
papillomaviru
hpv
vaccin
cervarix
although
other
studi
experiment
cell
culturederiv
vaccin
extran
protein
eg
serum
serum
deriv
present
final
product
serum
use
product
stimul
growth
cultur
cell
calcul
concentr
final
medium
must
exceed
part
per
million
antibiot
except
penicillin
analog
lactam
class
may
employ
cours
viral
vaccin
product
cell
cultur
antibiot
commonli
ad
low
concentr
neomycin
streptomycin
polymyxin
antibiot
present
packag
circular
must
contain
statement
concern
possibl
allerg
reaction
regard
requir
test
licens
biolog
product
fda
reevalu
appropri
select
requir
test
method
cite
cfr
exampl
gener
safeti
test
requir
fda
vaccin
cfr
manufactur
biolog
product
must
perform
test
gener
safeti
biolog
product
intend
administr
human
test
use
detect
extran
toxic
contamin
may
present
product
final
contain
everi
final
fill
lot
biolog
product
technolog
advanc
increas
abil
manufactur
control
analyz
manufactur
mani
biotechnologyderiv
biolog
product
decad
experi
product
fda
determin
mani
aspect
biolog
product
safeti
puriti
potenc
could
evalu
test
prescrib
part
anoth
exampl
fda
reexamin
test
requir
regul
regard
test
pyrogen
substanc
intraven
inject
rabbit
variabl
vivo
test
rabbit
pyrogen
test
consider
given
altern
method
limulu
amebocyt
lysat
lal
assay
endotoxin
discuss
fda
lal
assay
may
substitut
rabbit
pyrogen
test
may
provid
quantit
assess
endotoxin
content
product
abil
assess
endotoxin
level
vaccin
lot
may
also
provid
measur
manufactur
process
control
lot
lot
specif
test
design
provid
addit
assur
safeti
puriti
may
requir
eg
neurovirul
test
cell
cultur
anim
test
extran
virus
product
licens
manufactur
test
must
conduct
accord
exact
specif
manufactur
licens
applic
result
test
must
within
prescrib
limit
specifi
test
perform
lot
releas
hepat
b
vaccin
produc
use
recombin
dna
technolog
list
tabl
test
perform
lot
releas
typic
cell
cultureproduc
live
viral
vaccin
present
tabl
advers
reaction
biolog
product
defin
event
associ
use
biolog
product
regardless
whether
consid
product
relat
includ
side
effect
injuri
toxic
sensit
reaction
signific
failur
pharmacolog
action
advers
reaction
report
come
sever
sourc
manufactur
biolog
staff
us
pharmacopoeia
health
care
profession
common
sourc
consum
also
encourag
report
manufactur
also
report
data
concern
advers
reaction
postmarket
studi
foreign
sourc
publish
unpublish
scientif
literatur
result
report
advers
reaction
associ
vaccin
use
compil
enter
vaccin
advers
event
report
system
vaer
program
creat
outcom
nation
childhood
vaccin
injuri
act
ncvia
administ
jointli
fda
cdc
purpos
vaer
detect
possibl
signal
advers
event
associ
vaccin
vaer
collect
analyz
inform
report
advers
event
possibl
side
effect
occur
administr
uslicens
vaccin
vaer
accept
report
advers
event
may
associ
uslicens
vaccin
health
care
provid
manufactur
public
vaer
system
limit
routin
recommend
pediatr
vaccin
voluntari
report
suspect
advers
event
occur
administr
vaccin
also
accept
fda
continu
monitor
vaer
report
unexpect
pattern
chang
report
rate
advers
event
ncvia
also
mandat
develop
vaccin
inform
sheet
distribut
health
care
provid
adult
legal
repres
child
receiv
vaccin
recommend
routin
pediatr
use
acip
effort
made
ensur
suffici
written
inform
risk
diseas
risk
benefit
vaccin
would
provid
materi
includ
inform
diseas
vaccin
reaction
possibl
way
reduc
risk
major
advers
reaction
contraind
inform
group
high
risk
acquir
diseas
would
greatli
benefit
vaccin
exist
nation
vaccin
injuri
compens
program
feder
recommend
immun
schedul
cber
collabor
cdc
develop
inform
label
chang
usual
initi
manufactur
may
initi
cber
histor
manufactur
obtain
prior
approv
cber
label
chang
made
chang
cfr
mention
previous
also
appli
label
chang
allow
except
regul
test
vaccin
chang
add
strengthen
contraind
warn
precaut
advers
reaction
add
strengthen
instruct
dosag
administr
intend
increas
safe
use
delet
fals
mislead
unsupport
indic
use
effect
claim
regul
manufactur
could
effect
chang
time
submit
support
data
cber
without
preapprov
note
earlier
fda
regul
format
content
label
product
contain
carton
packag
insert
accompani
product
januari
fda
issu
final
druglabel
rule
commonli
refer
physician
label
rule
plr
amend
content
format
prescrib
inform
human
drug
biolog
product
new
format
intend
provid
health
care
profession
clear
concis
prescrib
inform
reorgan
critic
inform
streamlin
format
moreov
revis
make
simpler
health
care
profession
access
read
use
prescrib
inform
enhanc
safe
effect
use
prescript
drug
product
new
section
ad
label
highlight
section
contain
key
benefit
risk
inform
tabl
content
full
prescrib
inform
initi
label
new
vaccin
review
product
licens
process
describ
earlier
review
agenc
consid
draft
label
clinic
studi
submit
manufactur
ultim
indic
licens
product
driven
fda
review
support
clinic
data
submit
sponsor
subsequ
signific
chang
label
includ
new
indic
use
new
dosag
form
regimen
expand
patient
popul
receiv
product
addit
inform
regard
safeti
effect
requir
manufactur
submit
supplement
file
review
approv
cber
materi
review
ensur
fals
misleadingthat
comport
scientif
data
manufactur
develop
applic
data
acquir
subsequ
product
approv
unlik
product
label
promot
label
advertis
subject
clearanc
ahead
time
howev
similarli
monitor
mislead
claim
document
must
also
meet
standard
fair
balancethat
claim
efficaci
balanc
inform
product
safeti
sinc
earli
part
centuri
vaccin
combin
simultan
separ
administr
differ
vaccin
import
effect
mean
enhanc
effici
immun
program
combin
vaccin
compos
two
antigen
intend
induc
protect
multipl
infecti
diseas
sever
differ
serotyp
organ
antigen
contain
combin
vaccin
either
formul
togeth
manufactur
physic
mix
health
care
provid
administr
approach
requir
licensur
fda
unit
state
combin
diphtheria
tetanu
toxoid
toxoid
combin
pertussi
vaccin
dtp
licens
late
sinc
time
number
combin
grown
steadili
includ
individu
type
live
inactiv
polioviru
vaccin
sever
combin
measl
mump
rubella
vaccin
combin
haemophilu
influenza
type
b
conjug
vaccin
diphtheria
tetanu
toxoid
acellular
pertussi
dtap
hepat
b
vaccin
trival
influenza
vaccin
quadrival
influenza
vaccin
pneumococc
vaccin
multipl
serotyp
combin
hepat
hepat
b
vaccin
combin
dtap
inactiv
polioviru
hepat
b
vaccin
current
success
develop
new
vaccin
product
administ
first
year
life
complic
vaccin
schedul
put
special
pressur
desir
addit
combin
product
approach
might
option
futur
includ
combin
kill
antigen
alreadi
use
eg
dtap
haemophilu
type
b
conjug
pneumococc
conjug
hepat
b
polioviru
vaccin
live
viral
vaccin
routin
recommend
earli
life
measlesmumpsrubella
varicella
licensur
combin
live
viru
vaccin
avail
proquad
manufactur
merck
manufactur
process
preclin
clinic
studi
perform
licensur
new
combin
vaccin
intens
scrutin
product
develop
vaccin
complex
mixtur
contain
viral
bacteri
antigen
also
compon
preserv
adjuv
stabil
eg
gelatin
sorbitol
buffer
salt
particular
concern
compat
compon
final
combin
combin
vaccin
may
fail
manufactur
issu
physicochem
interact
product
biolog
interfer
among
combin
attenu
immun
agent
immunolog
interfer
detect
either
anim
studi
human
clinic
trial
preclin
immunogen
studi
may
use
determin
characterist
antibodyinduc
respons
subclass
affin
function
epitop
recognit
anim
model
may
help
compar
respons
combin
product
individu
vaccin
similarli
appropri
challeng
model
serv
bolster
human
data
collect
later
develop
sever
publish
exampl
clinic
interfer
administr
combin
vaccin
result
diminut
immun
respons
one
antigen
combin
compar
separ
administr
individu
compon
vaccin
one
exampl
observ
depress
respons
pertussi
antigen
one
experiment
haemophilu
type
b
conjugatedtap
combin
vaccin
demonstr
similar
combin
import
consider
preserv
accompani
one
compon
combin
product
must
deleteri
effect
anoth
compon
addit
impact
preserv
potenc
stabil
activ
compon
combin
must
evalu
similarli
one
compon
incorpor
adjuv
combin
could
affect
antigen
bind
bound
antigen
could
lost
previous
unbound
antigen
could
becom
adsorb
commonli
combin
rais
issu
relat
success
potenc
puriti
ident
steril
test
may
requir
altern
assay
strategi
potenc
test
individu
compon
alreadi
approv
use
licens
product
may
necessari
demonstr
test
still
produc
valid
inform
appli
new
combin
vaccin
exampl
vaccin
compon
may
test
earlier
bulk
stage
manufactur
rather
final
contain
adjuv
residu
antibiot
also
may
requir
adjust
made
steril
test
procedur
although
reaction
combin
vaccin
major
issu
safeti
need
care
evalu
new
product
addit
approv
combin
vaccin
separ
product
commonli
administ
simultan
reactiv
simultan
administ
vaccin
may
addit
gener
shown
enhanc
clinic
trial
requir
whether
compon
new
combin
product
previous
licens
studi
ordinarili
random
control
comparison
combin
individu
compon
vaccin
clinic
observ
reaction
sever
thousand
subject
coupl
laboratori
studi
immunogen
usual
suffici
assess
safeti
effect
combin
develop
new
combin
vaccin
continu
present
uniqu
challeng
vaccin
manufactur
well
regulatori
author
coordin
effort
dialogu
two
parti
import
help
bring
new
product
market
especi
complex
manufactur
clinic
evalu
increas
immun
program
unit
state
remark
effect
reduc
morbid
mortal
common
natur
transmit
infecti
diseas
eg
polio
measl
diphtheria
howev
emerg
infecti
diseas
eid
pandem
influenza
sever
acut
respiratori
syndrom
biolog
threat
potenti
intent
releas
gener
popul
also
pose
threat
global
public
health
vaccin
continu
import
medic
countermeasur
mcm
broad
rang
infecti
diseas
anthrax
smallpox
influenza
someth
new
unexpect
moreov
major
devast
infecti
diseas
tuberculosi
malaria
even
common
bacteria
staphylococci
increasingli
resist
avail
treatment
develop
safe
effect
vaccin
infecti
diseas
essenti
develop
mcm
vaccin
prevent
spread
infecti
diseas
whether
newli
emerg
intent
releas
present
numer
challeng
essenti
protect
public
health
regulatori
framework
place
evalu
vaccin
regardless
technolog
use
develop
howev
current
approach
develop
evalu
need
vaccin
alway
suffici
quickli
fulli
meet
global
domest
need
develop
essenti
mcm
must
take
full
advantag
scientif
innov
basic
scienc
product
develop
us
militari
implement
vaccin
program
protect
troop
sever
biolog
threat
howev
risktobenefit
ratio
protect
civilian
agent
bioterror
difficult
assess
present
one
licens
smallpox
vaccin
unit
state
sanofi
pasteur
biolog
new
smallpox
vaccin
also
develop
ind
applic
goal
seek
licensur
new
vaccinia
immun
globulin
prepar
treat
certain
complic
smallpox
vaccin
approv
one
licens
anthrax
vaccin
unit
state
anthrax
vaccin
adsorb
biothrax
emerg
biodefens
oper
current
licens
vaccin
avail
unit
state
plagu
tularemia
viral
hemorrhag
fever
virus
eg
ebola
marburg
lassa
new
world
arenavirus
howev
new
vaccin
agent
develop
ind
applic
signific
scientif
regulatori
challeng
associ
develop
test
new
vaccin
eid
biothreat
agent
vaccin
eid
like
use
novel
technolog
scienc
behind
technolog
may
complex
involv
eg
use
novel
cell
substrat
need
develop
altern
potenc
assay
need
identifi
surrog
marker
human
anim
predict
vaccin
effect
regard
bioterror
goal
fda
facilit
develop
vaccin
biolog
product
drug
diagnost
product
respond
bioterrorist
threat
effort
fda
work
interag
group
within
dhh
biomed
advanc
research
develop
author
cdc
nih
well
dod
depart
homeland
secur
prepar
respond
emerg
part
interag
group
fda
also
particip
set
broadbas
us
research
agenda
facilit
govern
prepared
bioterror
eid
key
activ
cber
includ
enhanc
regulatori
scienc
research
review
activ
area
expedit
develop
licensur
new
biolog
product
includ
vaccin
new
use
exist
product
licensur
counterbioterror
product
product
must
accept
qualiti
safeti
efficaci
potenc
profil
likewis
product
qualiti
control
must
also
complianc
cgmp
commit
continu
invest
regulatori
scienc
essenti
produc
mcm
public
health
threat
note
review
mcm
enhanc
ultim
applic
updat
regulatori
scienc
scientif
review
capac
help
strengthen
mcm
regulatori
process
thu
streamlin
mcm
develop
process
fda
undertak
new
initi
design
focu
augment
tool
use
assess
safeti
efficaci
qualiti
medic
product
particular
focu
mcm
get
concept
approv
process
effici
exampl
fda
regulatori
scienc
effort
assist
agenc
facilit
licensur
vaccin
emerg
diseas
biothreat
success
publicpriv
partnership
influenza
pandem
result
develop
approv
safe
effect
vaccin
pandem
record
time
alway
possibl
test
whether
vaccin
treatment
work
new
emerg
infecti
diseas
biothreat
threat
may
rare
even
nonexist
time
vaccin
therapi
need
develop
moreov
mani
vaccin
eid
biothreat
pose
difficult
challeng
regard
obtain
clinic
efficaci
data
mani
infecti
agent
toxin
human
efficaci
trial
feasibl
natur
exposur
longer
occur
eg
smallpox
occur
low
incid
occur
unpredict
manner
furthermor
human
challeng
studi
would
involv
expos
healthi
human
volunt
lethal
perman
disabl
agent
absenc
proven
therapi
counter
agent
perform
nonetheless
requir
licensur
vaccin
biothreat
agent
biologicalthat
safeti
efficaci
manufactur
consist
must
demonstr
anim
rule
describ
earlier
one
regulatori
mechan
allow
fda
address
challeng
obtain
clinic
efficaci
data
product
result
adequ
wellcontrol
anim
studi
establish
product
reason
like
provid
clinic
benefit
human
anim
test
often
avail
option
mani
diseas
lack
even
good
anim
model
anim
studi
technic
difficult
conduct
typic
limit
size
therefor
regulatori
scienc
need
develop
valid
improv
predict
model
regulatori
scienc
also
support
identif
valid
surrog
measur
product
efficaci
biomark
predict
efficaci
yet
avail
terror
threat
emerg
pathogen
major
global
infecti
diseas
effort
develop
refin
valid
new
biomark
may
lower
develop
cost
improv
speed
develop
safe
effect
product
unmet
public
health
need
summari
vaccin
eid
biothreat
agent
present
uniqu
issu
clinic
develop
evalu
fda
overal
plan
coordin
fda
necessari
move
product
toward
licensur
distribut
need
case
bioterrorist
threat
flexibl
agil
approach
product
develop
manufactur
need
speed
develop
vaccin
eid
biothreat
agent
fda
guidanc
engag
partner
critic
make
sure
product
move
futur
present
inadvert
contamin
vaccin
extran
infecti
agent
major
safeti
challeng
inher
risk
manufactur
process
microbi
contamin
occur
point
develop
biolog
product
manufactur
requir
control
place
ensur
ident
potenc
qualiti
puriti
vaccin
regul
licens
vaccin
requir
free
extran
materi
except
unavoid
manufactur
process
describ
approv
biolog
licens
applic
addit
current
fda
recommend
detect
evalu
cell
substrat
use
produc
viral
vaccin
describ
fda
final
guidanc
industri
entitl
character
qualif
cell
substrat
biolog
materi
use
product
viral
vaccin
infecti
diseas
indic
adventiti
agent
test
util
combin
method
strategi
perform
multipl
stage
manufactur
process
maxim
chanc
detect
contamin
use
multipl
strategi
test
provid
assur
extent
possibl
product
free
adventiti
agent
regulatori
requir
cgmp
also
ensur
product
manufactur
highest
standard
technolog
detect
discoveri
new
adventiti
agent
continu
evolv
rapid
pace
new
technolog
potenti
detect
adventiti
agent
previous
known
detect
cell
substrat
biolog
product
howev
technolog
also
introduc
scientif
regulatori
challeng
must
address
casebycas
basi
occasion
fda
encount
unexpect
find
licensur
may
potenti
impact
qualiti
safeti
product
one
exampl
occur
earli
discoveri
simian
viru
rhesu
monkey
kidney
cell
stock
use
produc
polioviru
product
inactiv
polio
vaccin
ipv
final
step
ipv
product
involv
formalin
inactiv
polioviru
rel
resist
formalin
inactiv
thu
low
level
live
remain
present
lot
ipv
feder
govern
requir
new
lot
ipv
manufactur
free
discoveri
endogen
avian
retrovirus
anoth
exampl
unexpect
find
brought
concern
fda
specif
qualiti
safeti
vaccin
produc
egg
cell
deriv
chick
embryo
case
aros
mid
highli
sensit
pcr
test
call
product
enhanc
revers
transcriptas
pert
assay
develop
revers
transcriptas
rt
enzym
present
retrovirus
presenc
rt
enzym
suggest
retrovirus
could
present
test
use
demonstr
previous
undetect
quantiti
revers
transcriptas
present
vaccin
produc
avian
cell
studi
fda
vaccin
industri
demonstr
endogen
avian
retroviru
defect
particl
induc
product
infect
cell
cultur
fda
conclud
base
result
along
long
safeti
record
vaccin
produc
hen
egg
benefit
vaccin
outweigh
potenti
risk
presenc
endogen
avian
retrovirus
vaccin
recent
unexpect
find
licens
vaccin
occur
involv
discoveri
porcin
circovirus
rotaviru
vaccin
team
investig
use
novel
metagenom
method
consist
viral
particl
purif
massiv
parallel
pyrosequenc
viral
sequenc
similar
search
search
adventiti
virus
eight
live
attenu
vaccin
oral
polio
viru
vaccin
rubella
viru
vaccin
measl
viru
vaccin
yellow
fever
viru
vaccin
varicella
viru
vaccin
two
rotaviru
vaccin
measlesmumpsrubella
vaccin
dna
sequenc
origin
porcin
detect
two
batch
gsk
live
attenu
rotaviru
vaccin
small
circular
viru
compos
singl
strand
dna
found
commonli
among
pig
known
caus
diseas
pig
anim
includ
human
investig
identifi
sequenc
rotaviru
vaccin
manufactur
merck
upon
notif
find
gsk
initi
studi
confirm
dna
present
vaccin
well
cell
bank
seed
vaccin
deriv
fda
began
laboratori
studi
also
confirm
presenc
dna
vaccin
find
indic
dna
like
present
sinc
earli
stage
vaccin
develop
includ
clinic
studi
merck
live
attenu
rotaviru
vaccin
test
merck
cber
potenti
pcv
contamin
fragment
dna
also
detect
evid
time
dna
pose
safeti
risk
preand
postmarket
studi
demonstr
highli
effect
prevent
seriou
gastrointestin
diseas
caus
rotaviru
addit
seriou
unexpect
safeti
concern
identifi
postmarket
surveil
addit
inform
gather
precautionari
measur
fda
recommend
march
clinician
public
health
profession
unit
state
temporarili
suspend
use
cber
sought
extern
input
find
rotarix
special
meet
vaccin
relat
biolog
product
advisori
committe
vrbpac
conven
may
gsk
fda
research
updat
committe
recent
find
statu
current
investig
investig
gsk
fda
includ
studi
design
determin
whether
dna
particl
associ
whether
infecti
viru
present
vaccin
whether
capabl
replic
vero
cell
mammalian
cell
includ
human
cell
line
time
conven
vrbpac
find
preliminari
discuss
vrbpac
ask
discuss
signific
recent
find
vaccin
implic
data
continu
use
need
addit
experi
data
base
avail
inform
feedback
vrbpac
cber
conclud
safeti
rotaviru
vaccin
support
avail
data
benefit
vaccin
known
substanti
outweigh
theoret
risk
therefor
cber
recommend
continu
use
rotaviru
vaccin
fda
consid
follow
reach
conclus
known
risk
theoret
risk
clinic
implic
safeti
concern
regard
agent
safeti
record
product
clinic
trial
control
postmarket
observ
studi
postmarket
passiv
surveil
eg
vaer
report
benefitrisk
profil
product
benefitrisk
determin
must
made
region
countri
cber
laboratori
investig
later
determin
dna
particl
associ
repres
near
full
length
dna
particl
replic
compet
cell
cultur
evid
found
replic
human
host
ie
seroconvers
cber
result
confirm
dna
fragment
present
follow
regulatori
action
taken
cber
fda
approv
revis
product
label
includ
inform
presenc
presenc
dna
fda
continu
assess
current
regulatori
recommend
test
vaccin
presenc
unknown
adventiti
agent
assist
assess
fda
sent
written
inquiri
manufactur
licens
viral
vaccin
andor
combin
vaccin
contain
viral
antigen
ask
provid
addit
inform
specif
fda
request
inform
regard
plan
manufactur
may
implement
addit
adventiti
agent
test
method
part
manufactur
process
method
becom
avail
includ
limit
screen
pcv
pcv
dna
well
addit
inprocess
test
adventiti
agent
may
recent
ad
report
fda
cber
comprehens
approach
address
unexpect
find
licens
product
involv
thorough
scientif
investig
analysi
find
safeti
risk
assess
seriou
regulatori
decis
made
fda
ie
suspens
use
avail
scientif
data
evalu
laboratori
studi
initi
feasibl
critic
regulatori
author
commun
manufactur
provid
guidanc
appropri
investig
plan
cber
vrbpac
avail
supplement
necessari
addit
expert
provid
scientif
expertis
guidanc
investig
process
must
transpar
public
public
health
entiti
notifi
kept
inform
investig
also
critic
commun
intern
commun
share
inform
harmon
effort
among
variou
nation
regulatori
author
detect
sequenc
vaccin
rais
complex
question
potenti
regulatori
implic
regard
specif
test
vaccin
regard
gener
use
advanc
analyt
method
character
vaccin
cell
substrat
power
new
methodolog
use
detect
sequenc
suggest
technolog
may
uncov
presenc
adventiti
agent
might
detect
current
method
implement
routin
use
method
benefit
well
challeng
risk
detect
method
adventiti
agent
continu
evolv
improv
new
method
may
higher
sensit
throughput
novel
virus
previous
known
frequent
discov
could
present
exist
new
cell
substrat
biolog
product
new
technolog
could
allow
detect
previous
unknown
undetect
agent
may
support
safe
product
develop
primari
respons
nra
ensur
qualiti
safeti
effect
pharmaceut
product
implement
strong
regulatori
system
facilit
goal
especi
critic
vaccin
inher
difficult
develop
character
manufactur
pharmaceut
product
fda
develop
manag
review
process
provid
regulatori
oversight
phase
vaccin
develop
advanc
across
wide
rang
scientif
disciplin
enhanc
prospect
develop
new
better
vaccin
novel
vaccin
approach
recombin
vaccin
novel
adjuv
deliveri
system
pose
regulatori
challeng
nra
howev
nra
dynam
flexibl
entiti
strive
develop
regulatori
requir
address
evolv
scienc
furthermor
nra
must
prepar
address
public
health
emerg
requir
expedit
approv
mechan
biolog
terrorist
event
pandem
influenza
emerg
infecti
diseas
